Journal article
Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease
C Song, S Burgess, JD Eicher, CJ O'Donnell, AD Johnson, J Huang, M Sabater-Lleal, FW Asselbergs, D Tregouet, SY Shin, J Ding, J Baumert, T Oudot-Mellakh, L Folkersen, NL Smith, SM Williams, MA Ikram, ME Kleber, DM Becker, V Truong Show all
Journal of the American Heart Association | WILEY | Published : 2017
Open access
Abstract
Background--Plasminogen activator inhibitor type 1 (PAI-1) plays an essential role in the fibrinolysis system and thrombosis. Population studies have reported that blood PAI-1 levels are associated with increased risk of coronary heart disease (CHD). However, it is unclear whether the association reflects a causal influence of PAI-1 on CHD risk. Methods and Results--To evaluate the association between PAI-1 and CHD, we applied a 3-step strategy. First, we investigated the observational association between PAI-1 and CHD incidence using a systematic review based on a literature search for PAI-1 and CHD studies. Second, we explored the causal association between PAI-1 and CHD using a Mendelian ..
View full abstractGrants
Awarded by National Heart, Lung, and Blood Institute
Funding Acknowledgements
This work was supported by NHLBI Intramural funds to O'Donnell and Johnson. Stephen Burgess is supported by a fellowship from the Wellcome Trust (100114).